// drug discovery

All signals tagged with this topic

theme-ai ai capabilities ai limitations drug discovery

Aug 3

Why AI Won't Shortcut Drug Discovery

Source: a16z

The venture capital narrative around AI-powered drug discovery treats molecular biology as a pure information problem solvable by scaling compute and model sophistication. The actual bottleneck is experimental validation and unknown biological complexity. Andreessen Horowitz's argument cuts against its own industry's hype cycle: even with perfect computational predictions, the wet-lab work, regulatory pathways, and fundamental biological surprises remain time-intensive and irreducible. Venture funding that treats biology as software-complete is capital deployed away from the grinding infrastructure—biotech manufacturing, clinical trial design, disease modeling—where pharmaceutical velocity actually lives.

theme-ai drug discovery

Mar 30

Eli Lilly bets $2.75 billion on AI-discovered drugs

Source: Semafor

Big Pharma’s largest commitment to AI-native drug discovery signals that generative AI has crossed from experimental lab tool to business-critical infrastructure in pharmaceutical R&D. The deal with Insilico Medicine—a company that has already moved 28 AI-designed candidates into development—suggests the bottleneck in drug discovery is shifting from scientific feasibility to manufacturing, regulatory approval, and clinical validation. This represents a structural shift in how pharmaceutical value gets created: companies that can integrate AI pipelines at scale may compress drug development timelines by years, fundamentally reshaping competitive advantage in an industry built on patent exclusivity windows.